Congenix is pleased to announce that they have been chosen to participate in a Phase II study for the treatment of rheumatoid arthritis with the use of monoclonal antibodies. Congenix will be the lead CRO and will manage 5 sites located in Russia, 7 sites in Hungary and 4 sites in Bulgaria for a total of 16 study sites. Congenix capabilities that will be used for this study will include regulatory affairs, site management, clinical monitoring and global project management. Congenix will also manage a local CRO that will provide data management and biostatistics.
This will be the third rheumatoid arthritis study that Congenix will be doing with this sponsor which acknowledges a growing appreciation for the job that Congenix has done in the past.
